Approved MS medication inhibits SARS-CoV-2 replication in vitro
Dimethyl fumarate (DMF), a multiple sclerosis (MS) drug, inhibited SARS-CoV-2 replication and the hyper-inflammatory immune response associated with COVID-19.
List view / Grid view
Dimethyl fumarate (DMF), a multiple sclerosis (MS) drug, inhibited SARS-CoV-2 replication and the hyper-inflammatory immune response associated with COVID-19.
Researchers have developed a new self-assembling three-dimensional (3D) ovarian cancer tumour model to recreate the in vitro disease more accurately.
Researchers found that the SARS-CoV-2 infection activates the NF-κB pathway, driving unchecked inflammation that contributes to total organ failure in COVID-19 patients.
According to researchers, Rab27b and epiregulin contribute to the development of radioresistance and could be targeted to improve glioblastoma patient survival.
The C5 compound targets the frameshifting element that allows SARS-CoV-2 to effectively replicate and marks the genome for destruction to stop the infection spreading.
According to a study, the lipid sphingosine can inhibit SARS-CoV-2 infection and could potentially be delivered in a nasal spray to prevent COVID-19 infections.
Researchers show CDK8 inhibition reduces cell plasticity without damaging cells and suggest their approach could have implications for autoimmunity and oncology.
Researchers have developed two novel trifluoromethylthio compounds which showed potent activity in protecting mice from Clostridioides difficile (C. diff) infection.
Scientists have demonstrated that AR-12 can inhibit SARS-CoV-2 replication and are working to initiate clinical trials evaluating the antiviral drug.
Richard Sachse discusses how immunotherapies targeting interleukin 15 (IL-15) signalling can be optimised to enhance their efficacy and limit off-target effects.
The non-infectious quantum dot probes are designed to enable researchers to safely study interactions between the SARS-CoV-2 Spike (S) protein and human cells.
SARS-CoV-2 entry into human cells is dependent on heparan sulfate and disrupting this interaction using heparin reduces infectivity of the coronavirus, find scientists.
The component, now developed into a drug called Ab8, was highly effective at treating and preventing SARS-CoV-2 infection in animal models.
The detailed analysis of adenosquamous cancer of the pancreas (ASCP) suggested FGFR and RORC were two promising therapeutic targets.
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…